Modeling future changes to the meningococcal serogroup C conjugate (MCC) vaccine program in England and Wales

Caroline L. Trotter, W. John Edmunds, Mary Ramsay, Elizbeth Miller

Research output: Contribution to journalArticlepeer-review

27 Citations (Scopus)

Abstract

The UK meningococcal serogroup C conjugate (MCC) vaccine program has successfully controlled serogroup C disease, due to high vaccine effectiveness and substantial herd immunity. However, children immunised at 2, 3 and 4 months of age receive only short-term direct protection and may be at risk of disease 15 months after vaccination. To investigate this we applied a mathematical model to predict the future epidemiology of serogroup C disease, with and without changes to the immunization schedule. Only a few cases of serogroup C disease were predicted to occur over the next few years because of persisting herd immunity, even without a change to the vaccine schedule. The inclusion of a booster dose is likely to improve the impact of the MCC program and reducing the number of doses in infancy will improve cost-effectiveness and create space in the schedule for the addition of other vaccines.

Original languageEnglish
Pages (from-to)68-73
Number of pages6
JournalHuman Vaccines
Volume2
Issue number2
DOIs
Publication statusPublished - 2006

Keywords

  • Conjugate vaccines
  • Mathematical models
  • Meningococcal disease
  • Vaccination

Fingerprint

Dive into the research topics of 'Modeling future changes to the meningococcal serogroup C conjugate (MCC) vaccine program in England and Wales'. Together they form a unique fingerprint.

Cite this